Allergy Therapeutics PLC's (LON:AGY) CFO Nick Wykeman and CEO Manuel Llobet join Proactive London's Katie Pilbeam to discuss their record profits for the six-month stage, with revenues up 7% at £54mln for the half to December 31.
The group also posted pre-R&D operating income of £20.5mln, up 18.5%. The firm has highlighted top-line momentum and operational efficiency for the growth in profitability.
The operating margin advanced four percentage points to 38% year on year, while the cash balance was an impressive £48.3mln, or a net £44mln, up from £37mln 12 months earlier.